Figure 4.
MRD measurement beyond 10−4improves prognostic stratification. (A-F) Kaplan-Meier graphs and risk tables depicting the proportion of patients with PFS (A and D), treatment-free survival (B and E), or OS (C and F) over time. Patients are stratified by detectability of MRD by the IGHV leader-based NGS assay (A-C) or by MRD depth (D-F). P values were obtained using 2-sided, nonstratified log-rank tests. A cross indicates right censoring. Cum., cumulative; MRD+, detectable MRD; uMRD5, undetectable MRD <10−5.
